Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Regeneron has more growth opportunities ahead ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Intellia has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is ...

Ophthalmology drug Vabysmo continued its stellar performance. The drug posed stiff competition to Regeneron’s REGN ophthalmology drug Eylea. Positive data from additional studies bode well for ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...